Abstract:Due to low ability to pass through the cell membrane and lack of proof in target delivery in vivo, anti-microRNA oligonucleotide (AMO) has poor target ability to microRNA in the cytoplasm, which results in low AMO targeting efficiency and limits AMO success in vivo application. In this study, AMO-phospholipids conjugates were developed to provide the characteristics of the two phospholipids to self -assemble via hydrophilic AMO and hydrophobic phospholipid tails to overcome the AMO backbone structures and enhance the AMO delivery efficiency. This AMO-phospholipids enveloped nanoparticles was radiolabeled with technetium -99 m (99mTc) for cellular delivery and in vivo imaging. Methods: 99mTc-radiolabeled miR-155 targeted AMO with partial 2 '-O-methyl (2 '-OMe) and phosphorothioate (PS) chemical modification was prepared via the conjugation to N-hydroxysuccinimide derivative of S-acetylmercaptoacetyltriglycine (NHS-MAG3). This radiolabeled AMO is chemically conjugated with phospholipids to form AMO-phospholipid. The AMO-phospholipids served as a component of nanoparticles to embed the hydrophobic part. AMO-phospholipids fused with polycarboxybetaine (PCB) based distearoyl phosphoethanolamine-polycarboxybetaine (DSPE-PCB) modified cationic lipids to form AMO-phospholipidcoated nanoparticles (AMO-NP), which delivered AMO into cytoplasm in vitro and into tumor in vivo. Further, this radiolabeled AMO-NP was confirmed by gel electrophoresis and evaluated for its serum stability, cytotoxicity, inhibitory ability and cellular uptake in HeLa cells, as well as the fluorescent distribution in vitro. Moreover, its distribution and in vivo imaging were performed HeLa tumor -bearing mice after the injection of radiolabeled AMO-NP. Results: The gel electrophoresis of 99mTc labeled AMO-NP showed good conjugation between AMO and 99mTc. It also kept highly stable in human serum. Western blotting results showed that AMO-NP could up -regulate the expression of C/EBP beta protein, one of target proteins of miR-155 in HeLa cells, proving the ability in the specific binding and inhibition. The cellular uptake of 99mTc labeled AMO-NP was significantly higher than that of bare AMO. Furthermore, FAM labeled AMO-NP displayed its ability of specific and effective distribution in tumor cells and a good stability in cellular level. After the system administration, the distribution and in vivo imaging results revealed the significant difference between 99mTc labeled AMO-NP and negative control probe in HeLa tumor xenograft models, which suggested the specific binding and effective delivery ability of 99Tc labeled AMO-NP in vivo. Conclusion: This study supports the effectiveness and efficiency of cellular and in vivo delivery of 99mTc radiolabeled AMO-NP in cervical tumor and suggests a prospective candidate for future tumor imaging.

Improved Synthesis and Biological Evaluation of Tc-99m Radiolabeled Amo for Mirna Imaging in Tumor Xenografts

Noninvasive Visualization of Microrna-155 in Multiple Kinds of Tumors Using a Radiolabeled Anti-Mirna Oligonucleotide

Optimized Preparation of a 99m Tc-Radiolabeled Probe for Tracing MicroRNA

One-step synthesis of a radioiodinated anti-microRNA-21 oligonucleotide for theranostics in prostate tumor xenografts

[In Vivo Imaging of Breast Tumors by a 99mtc Radiolabeled Probe Targeting Microrna-155 in Mice Models].

Radiolabeled AMO-phospholipid Enveloped Nanoparticle for Cellular Delivery and in Vivo Imaging in Cervical Cancer Xenografts

Noninvasive Visualization Of Rna Delivery With Tc-99m-Radiolabeled Small Interference Rna In Tumor Xenografts

A Novel Tetrapeptide for Chelator-Free Radiolabeling in Optimized Preparation of 99Mtc-Radiolabeled Oligonucleotides.

Study on in vivo imaging of 99Tcm-hTERT mRNA as antisense molecular probe in breast cancer tumor-bearing nude mice

Preparation and Optimization of (99m)~Tc-radiolabeled Antisense Oligonucleotide Targeting microRNA

In-vitro Inhibitory Activity and In-vivo Biodistribution of ~(99)Tc~m Radiolabeled Small Interference RNA

Therapeutic Delivery of Mir-143 Targeting Tumor Metabolism in Poorly Differentiated Thyroid Cancer Xenografts and Efficacy Evaluation Using 18F-FDG Micropet-Ct

Synthesis, Radiolabeling And Biodistribution Studies Of [Tc-99m(Co)(3)(Mn-Tz-Bpa)](+) In Tumor-Bearing Mice

Synthesis, radiolabeling and biodistribution studies of [<sup>99m</sup>Tc(CO)<sub>3</sub>(MN-TZ-BPA)]<sup>+</sup> in tumor-bearing mice

99mTc-Labeled Iron Oxide Nanoparticles for Dual-Contrast ( T 1 / T 2 ) Magnetic Resonance and Dual-Modality Imaging of Tumor Angiogenesis

In Vitro Research on MicroRNA-155 Targeted Radiolabeled Oligonucleotide in Breast Cancer Cells

In-vitro Inhibitory Activity and In-Vivo Biodistribution of "9"9tc"m Radiolabeled Small Interference RNA

A novel molecular probe:experimental study in vivo in nude mice bearing tumor

Preparation and Tumor Cell Uptake of Sirna Probe Radiolabeled with Technetium-99m Targeting on Htert Gene

[In-Vivo Tumor Imaging by Radiolabeled RNA Probe Targeting Telomerase].

Dual-Signal Amplification Strategy Based on Catalytic Hairpin Assembly and APE1-Assisted Amplification for High-Contrast Mirna Imaging in Living Cells.